Circulating IgG Fragments for Gastric Cancer and Esophageal Cancer
Eugene I. Goufman,
Nataliia B. Tikhonova,
Andrey P. Aleksankin,
Karina B. Gershkovich,
Alexander A. Stepanov,
Irina I. Stepanova,
Liudmila M. Mikhaleva,
Natalia V. Nizyaeva,
Olga V. Kovaleva,
Alexander A. Alferov,
Yury B. Kuzmin,
Nikolay E. Kushlinskii
Affiliations
Eugene I. Goufman
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”, 117418 Moscow, Russia
Nataliia B. Tikhonova
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”, 117418 Moscow, Russia
Andrey P. Aleksankin
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”, 117418 Moscow, Russia
Karina B. Gershkovich
N. M. Emanuel Institute for Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia
Alexander A. Stepanov
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”, 117418 Moscow, Russia
Irina I. Stepanova
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”, 117418 Moscow, Russia
Liudmila M. Mikhaleva
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”, 117418 Moscow, Russia
Natalia V. Nizyaeva
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”, 117418 Moscow, Russia
Olga V. Kovaleva
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology», 115478 Moscow, Russia
Alexander A. Alferov
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology», 115478 Moscow, Russia
Yury B. Kuzmin
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology», 115478 Moscow, Russia
Nikolay E. Kushlinskii
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology», 115478 Moscow, Russia
Blood serum of patients with gastric (n = 68) and esophageal (n = 43) cancer was assessed for proteolytic fragments of IgG. Serum samples of 20 healthy donors were used as a control. We analyzed indicators of hemostasis (prothrombin time, fibrinogen, plasminogen activity, a2-antiplasmin activity, protein C activity) in blood plasma and the level of total IgG in the blood serum. The median IgG-LysK of healthy donors was lower than in esophageal cancer and in patients with gastric cancer. ROC-analysis showed high sensitivity (91%) and specificity (85%) in the group with esophageal cancer but 68% and 85%, respectively, in patients with gastric cancer. Analysis of false negatives IgG-LysK in cancer patients showed that most patients had an advanced stage of cancer accompanied by metastases. Total IgG in the plasma of patients with false-negative IgG-LysK values was 30% lower than in samples with positive values, while the level of a2-antiplasmin was increased and the prothrombin time was shorter. These changes in blood homeostasis may be the reason for an increase in the proportion of false-negative values of the IgG-LysK coefficient. Circulatory IgG-LysK levels increase in the early stages of such cancers as gastric and esophageal cancers. Thus, when used in a panel with other more specific markers for these pathologies, this indicator can significantly increase the early detection of cancer.
